Endometriosis - Global Strategic Business Report

Description: This report analyzes the worldwide markets for Endometriosis in US$ Million. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Rest of World.

Annual estimates and forecasts are provided for the period 2015 through 2022. Also, a six-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research.

Company profiles are primarily based on public domain information including company URLs. The report profiles 38 companies including many key and niche players such as -

AbbVie Inc,
AEterna Zentaris Inc.
Astellas Pharma Inc.
AstraZeneca Plc
Bayer HealthCare Pharmaceuticals, Inc.

Contents: I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

Study Reliability and Reporting Limitations
Disclaimers
Data Interpretation & Reporting Level
Quantitative Techniques & Analytics
Product Definitions and Scope of Study

II. EXECUTIVE SUMMARY

1. INDUSTRY OVERVIEW
   Endometriosis Statistics Fact Sheet
   A Quick Market Primer
   Poor Efficacy and Safety Profiles of Existing Drugs Lead to Unmet Medical Needs
   Key Endometriosis Drugs on the Market
   Table 1: Leading Endometriosis Drugs on the Market (2015): Percentage Market Share Breakdown of Depo Provera, Eligard, Lupron, Visanne, Zoladex, and Others (includes corresponding Graph/Chart)
   The Pipeline Review
   Key Endometriosis Drugs in the Pipeline: 2016
   Current and Future Analysis
   Emerging Treatment for Endometriosis & Endometrial Cancer
   Global Awareness Campaigns and Efforts

2. ENDOMETRIOSIS & ITS TREATMENT
   AN OVERVIEW
   Introduction
   Occurrence of Endometriosis in Women
   Causes and Symptoms
   Causes
   Estrogen Theory
   Müllerianosis Theory
   Retrograde Menstruation Theory
   Coelomic Metaplasia Theory
   Hereditary Factors
   Environmental Factors
   Dioxin Behavior in the Body
   Birth Defects
   Other Causes
   Symptoms of Endometriosis
Reasons for Pain due to Endometriosis
Endometriosis and Infertility
Kinds of Endometriosis
Reproductive Area Endometriosis
Uterosacral/Presacral Nerve Endometriosis
Cul-de-Sac ("Pouch of Douglas") Endometriosis
Gastrointestinal Endometriosis
Pleural (lung/chest cavity/diaphragmatic) Endometriosis
Urinary Tract (kidneys, ureters, bladder and urethra) Endometriosis
Skin Endometriosis
Sciatic Endometriosis
Stages of Endometriosis
Diagnosis of Endometriosis
Major Diagnostic Techniques
Pelvic Exam
Laparoscopy
Other Diagnostic Procedures
A New Non-invasive Test for the Diagnosis of Endometriosis
Endometriosis Markers
Counseling of patients
Recurrence of Endometriosis
Endometriosis & Infertility
Miscarriage
Endometriosis & Thyroid Autoimmunity
Relationship between Endometriosis and Autoimmune Disease
Endometriosis & Cancer
Associations & Research Centers
The Endometriosis Association
Endometriosis Research Center

3. TREATMENT OF ENDOMETRIOSIS
Endometriosis & Available Treatment Options
Endometriosis Treatment: In a Nutshell
I. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
II. Hormonal Therapy
Gonadotropin Releasing Hormone (GnRH) Agonists
Select Major GnRH-Agonists for Endometriosis Treatment
Lupron, Zoladex and Synarel
The Major Drugs
Abbott's Lupron® (Leuprolelin)
AstraZeneca's Zoladex® (Goserelin)
Pfizer's Synarel (Nafarelin Acetate)
Add-back Medication
Progestogens
Select Major Progestins for Endometriosis Treatment
Combined Oral Contraceptive Pill
Danazol and Other Suppressive Steroids
Chinese Herbs
More Effective than Danazol or Gestrinone
Aromatase Inhibitors
III. Non-hormonal Therapy
Anti-Angiogenic Agents
Selective COX-2 Inhibitors
TNF-Alpha Inhibitors
IV. Surgical Techniques
V. Complementary Therapies
Long-term Approach to Pain
Lifestyle Modifications
Chinese Herbs
Treatment for Endometriosis-related Infertility
Hormonal Treatment
Minimal to Mild Endometriosis
Moderate-Severe Endometriosis
Surgical Treatment
Minimal-Mild Endometriosis
Moderate-Severe Endometriosis
Treatment for Ovarian Endometriosis
Surgical Vs. Medicinal Interventions
Medicinal Interventions
Advantages
Disadvantages
Surgery
Advantages
Disadvantages
In-vitro Fertilization
Other Treatment

4. SELECT CLINICAL TRIALS/PRODUCT INNOVATIONS & APPROVALS
Virexxa Receives FDA Clearance to Proceed to Phase II
OBE2109 by ObsEva Receives IND Clearance
Galena Biopharma Presents Phase 1/2a Data on Endometrial Cancer Immunotherapies
AbbVie and Neurocrine Report Positive Phase 3 Trial Data of Elagolix
ValiRx Plc to Begin Endometriosis Clinical Research with its VAL201
Aurobindo Pharma Receives FDA Approval to Market Tablets for Endometriosis Treatment
Lumenis to Introduce UltraPulse DUO CO2 laser system and FemTouch Solution
Bayer Launches Phase II Trials of vilaprisan for Endometriosis Treatment
Nippon Shinyaku Conducts Phase I Evaluation of NS 580 for Endometriosis Therapy
Teleflex to Showcase its Surgical Solutions for Endometriosis
ValiRx Plc Receives Patent Grant for VAL201
Hologic Launches NovaSure 6mm Endometrial Ablation System
Endometriosis Research Foundation Releases Standardized Data Tools
ESHRE Develops App for Endometriosis Management

5. RECENT INDUSTRY ACTIVITY
Takeda and Roivant Partner to Form Myovant
Evotec-Bayer Collaboration Reaches Important Clinical Milestones for Endometriosis Therapy
ObsEva and Kissei Pharmaceutical Enter Into Collaboration Agreement for KLH-2109
Aeterna Zentaris Adds New Clinical Site for Endometrial Cancer Therapy Phase 3 Trial
VolitionRx Enters Into Collaboration with University of Oxford for Endometriosis Clinical Solution
SRI International and Nobelpharma Enter Into Licensing Agreement for SR16234

6. FOCUS ON SELECT GLOBAL PLAYERS
AbbVie Inc. (US)
AEterna Zentaris Inc. (Canada)
Astellas Pharma Inc. (Japan)
AstraZeneca Plc. (UK)
Bayer Healthcare Pharmaceuticals, Inc. (US)
Debiopharm Group (Switzerland)
Evotec AG (Germany)
Kissei Pharmaceutical Co., Ltd. (Japan)
Neurocrine Biosciences, Inc. (US)
ObsEva SA (Switzerland)
Pfizer, Inc. (US)
Repros Therapeutics, Inc. (US)
Roivant Sciences Ltd. (US)
Takeda Pharmaceutical Company Limited (Japan)
ValiRx Plc (UK)

7. GLOBAL MARKET PERSPECTIVE
Table 2: World Recent Past, Current & Future Analysis for Endometriosis Drugs by Geographic Region
US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
Table 3: World Historic Review for Endometriosis Drugs by Geographic Region
US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)
Table 4: World 14-Year Perspective for Endometriosis Drugs by Geographic Region
III. MARKET

1. THE UNITED STATES
A. Market Analysis
United States: The Largest Market for Endometriosis
Endometriosis Associations Increase Awareness
Newer Diagnostic Methods Yet to Expand Across the Country
Key Endometriosis Drugs on the Market
Product Launches
Strategic Corporate Developments
Select Key Players
B. Market Analytics
Table 5: The US Recent Past, Current & Future Analysis for Endometriosis Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
Table 6: The US Historic Review for Endometriosis Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

2. CANADA
A. Market Analysis
Product Launch
Strategic Corporate Development
Select Key Players
B. Market Analytics
Table 7: Canadian Recent Past, Current & Future Analysis for Endometriosis Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
Table 8: Canadian Historic Review for Endometriosis Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

3. JAPAN
A. Market Analysis
Clinical Trial
Select Key Players
B. Market Analytics
Table 9: Japanese Recent Past, Current & Future Analysis for Endometriosis Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
Table 10: Japanese Historic Review for Endometriosis Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

4. EUROPE
Market Analysis
Table 11: European Recent Past, Current & Future Analysis for Endometriosis Drugs by Geographic Region/Country
France, Germany, Italy, UK, Spain, and Rest of European Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
Table 12: European Historic Review for Endometriosis Drugs by Geographic Region/Country
France, Germany, Italy, UK, Spain, and Rest of European Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)
Table 13: European 14-Year Perspective for Endometriosis Drugs by Geographic Region/Country
Percentage Breakdown of Dollar Sales for France, Germany, Italy, UK, Spain, and Rest of European Markets for Years 2009, 2016 and 2022 (includes corresponding Graph/Chart)

4a. FRANCE
A. Market Analysis
Programmes to Maintain Endometriosis Database
B. Market Analytics
Table 14: French Recent Past, Current & Future Analysis for Endometriosis Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
Table 15: French Historic Review for Endometriosis Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)
4b. GERMANY
A. Market Analysis
Clinical Trial
Strategic Corporate Development
Evotec Ag
A Key Player
B. Market Analytics
Table 16: German Recent Past, Current & Future Analysis for Endometriosis Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
Table 17: German Historic Review for Endometriosis Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

4c. ITALY
Market Analysis
Table 18: Italian Recent Past, Current & Future Analysis for Endometriosis Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
Table 19: Italian Historic Review for Endometriosis Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

4d. THE UNITED KINGDOM
A. Market Analysis
Product Launches
Select Key Players
B. Market Analytics
Table 20: The UK Recent Past, Current & Future Analysis for Endometriosis Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
Table 21: The UK Historic Review for Endometriosis Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

4e. SPAIN
Market Analysis
Table 22: Spanish Recent Past, Current & Future Analysis for Endometriosis Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
Table 23: Spanish Historic Review for Endometriosis Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

4f. REST OF EUROPE
A. Market Analysis
Product Launches
Strategic Corporate Developments
Select Key Players
B. Market Analytics
Table 24: Rest of Europe Recent Past, Current & Future Analysis for Endometriosis Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
Table 25: Rest of Europe Historic Review for Endometriosis Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

5. ASIA-PACIFIC
A. Market Analysis
Proteomics Being Researched for Endometriosis Therapeutics (Australia)
Select Key Player
B. Market Analytics
Table 26: Asia-Pacific Recent Past, Current & Future Analysis for Endometriosis Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
Table 27: Asia-Pacific Historic Review for Endometriosis Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

6. REST OF WORLD
A. Market Analysis
Product Launch
B. Market Analytics
Table 28: Rest of World Recent Past, Current & Future Analysis for Endometriosis Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
Table 29: Rest of World Historic Review for Endometriosis Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

IV. COMPETITIVE LANDSCAPE Total Companies Profiled: 38 (including Divisions/Subsidiaries 40)
The United States (11)
Canada (3)
Japan (6)
Europe (15)
- France (1)
- Germany (3)
- The United Kingdom (2)
- Rest of Europe (9)
Asia-Pacific (Excluding Japan) (4)
Middle-East (1)

Order by Fax - using the form below
Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: Endometriosis - Global Strategic Business Report
Web Address: http://www.researchandmarkets.com/reports/1824128/
Office Code: SC

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Format Type</th>
<th>Quantity Options</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) - Single User</td>
<td>✅</td>
<td>USD 4950</td>
</tr>
<tr>
<td>Electronic (PDF) - 1 - 5 Users</td>
<td>✅</td>
<td>USD 6930</td>
</tr>
<tr>
<td>Electronic (PDF) - 1 - 10 Users</td>
<td>✅</td>
<td>USD 9405</td>
</tr>
<tr>
<td>Electronic (PDF) - 1 - 15 Users</td>
<td>✅</td>
<td>USD 11880</td>
</tr>
</tbody>
</table>

* The price quoted above is only valid for 30 days. Please submit your order within that timeframe to avail of this price as all prices are subject to change.

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: Mr ☐ Mrs ☐ Dr ☐ Miss ☐ Ms ☐ Prof ☐
First Name: ___________________________ Last Name: ___________________________
Email Address: * ___________________________
Job Title: ___________________________
Organisation: ___________________________
Address: ___________________________
City: ___________________________
Postal / Zip Code: ___________________________
Country: ___________________________
Phone Number: ___________________________
Fax Number: ___________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by Wire Transfer: Bank details will be provided on the invoice which you will receive after you place your order with us.

If you have a Marketing Code please enter it below:

Marketing Code: ________________________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World